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Background: The aim is to assess the time-density curves (TDCs) and correlate the histologic results for small (≤ 2 cm)
PDA and surrounding parenchyma at triphasic Multidetector-row CT (MDCT).
Methods: Triphasic MDCT scans of 38 consecutive patients who underwent surgery for a small PDA were retrospectively
reviewed. The TDCs were analyzed and compared with histologic examination of the PDA and pancreas upstream/
downstream in all cases. Three enhancement patterns were identified: 1) enhancement peak during pancreatic
parenchymal phase (PPP) followed by a rapid decline on portal venous phase (PVP) and delayed phase (DP) at 5 minutes
(type 1 pattern: normal pancreas); 2) maximum enhancement in PVP that gradually decreases in DP (type 2 pattern: mild
chronic pancreatitis or PDA with mild fibrous stroma); 3) progressive enhancement with maximum peak in DP (type 3
pattern: severe chronic pancreatitis or PDA with severe fibrous stroma). A p value less than 0.05 was considered
statistically significant. Sensitivity was calculated for PDA detection and an attenuation difference with the surrounding
tissue of at least 10 HU was considered.
Results: PDA showed type 2 pattern in 5/38 cases (13.2%) and type 3 pattern in 33/38 cases (86,8%). Pancreas upstream
to the tumor had type 2 pattern in 20/38 cases (52,6%) and type 3 pattern in 18/38 cases (47,4%). Pancreas downstream
to the tumor had type 1 pattern in 19/25 cases (76%) and type 2 pattern in 6/25 cases (24%). Attenuation difference
between tumor and parenchyma upstream was higher of 10 UH on PPP in 31/38 patients (sensitivity = 81.6%), on PVP in
29/38 (sensitivity = 76.3%) and on DP in 17/38 (sensitivity = 44.7%). Attenuation difference between tumor and
parenchyma downstream was higher of 10 UH on PPP in 25/25 patients (sensitivity = 100%), on PVP in 22/25
(sensitivity = 88%) and on DP in 20/25 (sensitivity = 80%). Small PDAs were isodense to the pancreas upstream to the
tumor, and therefore unrecognizable, in 8 cases (8/38; 21%) at qualitative analysis and in 4 cases (4/38; 10,5%) at
quantitative analysis.
Conclusions: The quantitative analysis increases the sensitivity for detection of small PDA at triphasic MDCT.
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Detection of pancreatic ductal adenocarcinoma (PDA) by
imaging is essential for an accurate tumor staging and for
choosing an adequate treatment [1].
Although current Multidetector-row Computed Tomog-
raphy (MDCT) protocols [2-6] maximize the attenuation
differences between the hypovascular tumor and the sur-
rounding parenchyma, about 10% of PDA is isoattenuating
to the pancreatic parenchyma underlying [4-9], making
diagnosis more difficult; in these cases to detect the PDA,
the secondary signs (e.g. main pancreatic duct dilatation or
the interrupted duct sign) can be extremely useful [7,8].
Histopathological characteristics of tumor and surround-
ing parenchyma represent the causes of misdiagnosis owing
to obscurity of the lesion on a CT scan [5,8,10,11]. A similar
degree of fibrosis in the tumor and surrounding pancreatic
parenchyma, resulting in the form of mild or severe chronic
obstructive pancreatitis, may determine a similar enhance-
ment on MDCT precluding the identification of PDA.
The knowledge by triphasic MDCT of the different en-
hancement patterns of PDA, pancreatic parenchyma up-
stream (toward the tail) and downstream (toward the head)
to the tumor and histopathological features related are es-
sential to increase the sensitivity of MDCT in the detection
of PDA.
Our aim is to correlate the time-density curves (TDCs) at
triphasic MDCT with histological characteristics for small
(≤ 2 cm) PDA and surrounding parenchyma.Methods
Patient selection
From a retrospective review of pathological reports and
surgical records we identified 127 patients with PDA who
underwent pancreaticoduodenectomy, distal pancreatec-
tomy or total pancreatectomy at our institution between
January 2006 and March 2012.
Tumors without histological examination of surrounding
tissue or greater than 2 cm, tumors with atrophy of the up-
stream pancreas (n = 73) and patients with incomplete or
inadequate helical Computed Tomography (CT) protocol
(n = 16) were excluded from the study.
The final study population consists of 38 patients
(26 males and 12 females, mean age 67.6 years, range age
54–88 years) who underwent an identical triphasic MDCT
protocol, ultrasonography and/or Magnetic Resonance im-
aging and in whom the histological and MDCT examin-
ation of PDA and pancreas upstream/downstream to the
tumor was performed.
For this retrospective study the evaluation of data ob-
tained in the clinical routine were followed and informed
consent was obtained in all patients. Information gathered
on this population was performed in compliance with the
Declaration of Helsinki principles.Histological evaluation
The surgical specimens of the pancreaticoduodenectomy,
distal pancreatectomy or total pancreatectomy were exam-
ined for the PDA (n = 38) and pancreatic parenchyma up-
stream (n = 38) and downstream (n = 25) to the tumor.
The surgical specimens for pancreatic parenchyma down-
stream to the tumor were not available in 13 patients be-
cause, in these patients, the PDA was localized in the
uncinate process.
PDA histologically showed high cellularity of tumor
cells with dense mild or abundant fibrosis, mucin and/or
necrosis.
Mild chronic pancreatitis histologically showed a lim-
ited involvement of pancreatic parenchyma upstream
and downstream to the tumor corresponding to fibrosis,
dilatation of small ducts and occasional presence of in-
flammatory cells.
Severe chronic pancreatitis histologically showed dif-
fuse fibrosis, low presence of inflammatory cells, loss of
acini and dilatation of the portion of the Wirsung’s duct
in the upstream pancreatic parenchyma to the tumor.Multislice CT protocol
CT scans were performed with 16 slice (Light Speed Plus
and Light Speed Pro 16, GE Healthcare, Milwaukee,
USA) and 64 slice (Philips Brilliance, Nederlands, United
Kingdom, and Light Speed Pro 64, GE Healthcare,
Milwaukee, USA) MDCT. The injected vein was initially
tested with 30 mL of saline solution to ensure proper func-
tion. Before the examination, 600–900 ml of water per os,
in order to improve the visualization of the relationships
between pancreatic head and duodenum, were given.
We use bolus tracking, positioning a circular region of
interest (ROI) on the abdominal aorta at the level of the
celiac axis and using an enhancement threshold of 150
Hounsfield Unit (HU). After a scout-view of the entire
abdomen and an unenhanced CT phase of the upper abdo-
men, triple phase acquisition includes a pancreatic paren-
chymal phase (PPP) (started 25 seconds after threshold of
150 HU aortic enhancement), a portal venous phase (PVP)
(started 40 seconds after the end of PPP acquisition)
and a delayed phase (DP) (after 5-minutes to the start of
injection). Nonionic iodinated contrast agent (Iopami-
dolo, Iopamiro 370 mgI/ml; Bracco, Milan, Italy and
Iopromide, Ultravist 370 mgI/ml Schering AG, Berlin,
Germany) is injected in a quantity ranged from 120 ml
to 150 ml at a rate of 4 mL/sec from an antecubital vein
using a 18 gauge needle.
Slice thickness was 2.5 mm, gantry rotation speed of
0.75 seconds, reconstruction index 1.25; beam pitch:
0,935:1; 120 kilovolts peak (kVp) and automatic tube
current (milliampere; mA) modulation using z-axis (Auto
mA technique) or dose modulation (Z-DOM).
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onal or curved multiplanar reconstructions (MPR).
Images analysis
Image analysis had two steps: qualitative analysis and
quantitative analysis of PDA and pancreatic parenchyma
up/downstream to the tumor.
The qualitative and quantitative analysis were performed
on a workstation for reporting and image processing
(Advantage Workstation 4.2 GE Healthcare, Milwaukee,
USA and MagicView, Philips Medical Systems, Best,
Netherlands).
For the qualitative analysis of PDA, all images were
retrospectively assessed by two radiologists with more than
20 years of experience in abdominal CT interpretation and
the findings were made in consensus. The attenuation of
PDA and pancreatic parenchyma up/downstream to the
tumor was classified as hyperattenuation, isoattenuation
and hypoattenuation on each phase of CT scan. Ancillary
findings in diagnosis of pancreatitis and in detection of
tumor were: distortion of the outlines of the pancreas,
margins and homogeneity of tumor, dilatation of main
pancreatic duct upstream to the tumor and of extrahepatic
bile ducts.
The regions of interest (ROIs) were determined by one
of the authors for PDA and pancreas upstream/down-
stream to the tumor. The quantitative analysis of PDA was
performed to determine the tumor-to-surrounding pan-
creas attenuation difference, defined as the difference in
attenuation between the tumor and the pancreas upstream
or downstream. Attenuation values were obtained in a cir-
cular ROI ranged in size from 0.2 to 1 cm2. The ROI
tumor values in the PPP, PVP and DP were measured in at
least half of the mass from the portion of the tumor that
had the greatest attenuation on the arterial phase images.
A tumor ROI of approximately 0.5 cm2 (range, 0.32–
0.56 cm2) was maintained. Measurement of the attenu-
ation in the pancreatic parenchyma up/downstream to
the tumor was obtained at 1 cm from the margins of the
tumor and excluded visible vessels, pancreatic ducts,
cystic areas, calcifications or necrosis. A constant ROI
area of parenchyma up-/downstream of approximately
1.0 cm2 (range, 0.5–1.0 cm2) was maintained. At leastTable 1 CT attenuation patterns of tumor, pancreas upstream
analysis by triphasic CT
Pancreas upstream to the tumo
CT pattern of tumor attenuation Hyperdense Hypodense
PPP 8 (21.1) 20 (52.6)
PVP 4 (10.3) 22 (57.9)
DP 10 (26.3) 6 (15.8)
PPP: pancreatic parenchymal phase; PVP = portal venous phase; DP = delayed phase
25/38 patients. Number in brackets indicates the percentage.three measurements were performed in each tumor
and in the up-/downstream parenchyma and the re-
sults were averaged.
A difference of more than 10 HU in mean attenuation
between the tumor and the pancreatic parenchyma up-
stream and/or downstream was considered meaningful
[4]. The difference in attenuation between each tumor and
surrounding parenchyma was calculated as follow:
Attenuation difference =mean tumor attenuation val-
ues - mean pancreas upstream and/or downstream at-
tenuation values.
A positive difference of enhancement indicates that the
lesion is hyperdense compared with surrounding paren-
chyma and vice versa. When the difference in attenuation
between the lesion and pancreatic parenchyma upstream
or downstream to the lesion presents values <10 HU, the
lesions are unrecognizable (PDA so called “isodense”).
After the assessment of PDA and pancreatic parenchyma
up-/downstream to the tumor attenuation, the time-density
curves (TDCs) of PDA and up-/downstream pancreatic
parenchyma in each patient were generated and categorized
into three patterns:
 Type 1 pattern: rapid rise to a peak on PPP followed
by a rapid decline;
 Type 2 pattern: slow rise to a peak on PVP followed
by a slow decline;
 Type 3 pattern: a progressive enhancement with
peak on DP.
The patterns of TDCs from triphasic CT measured at
the PDA, pancreas upstream and downstream were then
compared with the corresponding histological pancreatic
sections in each patient.
Statistical analysis
For comparative analysis of the average values of attenu-
ation (mean values in HU ± standard deviation [SD]) of
PDA, parenchyma upstream and downstream was used
Student t test. A p value less than 0.05 was considered sta-
tistically significant. Sensitivity was calculated for the identi-
fication of PDA compared with upstream and downstream
pancreas in each CT phase. For the statistical analysis hasand pancreas downstream to the tumor at qualitative
r (n = 38)* Pancreas downstream to the tumor (n = 25)**
Isodense Hyperdense Hypodense Isodense
10 (26.3) - 25 (100) -
12 (31.6) - 22 (88) 3 (12)
22 (57.9) 6 (24) 14 (56) 5 (20)
. *CT/histologic assessment in 38/38 patients; **CT/histologic assessment in
Table 2 CT attenuation patterns of tumor, pancreas upstream and pancreas downstream to the tumor at quantitative
analysis by triphasic CT
Pancreas upstream to the tumor (n = 38)* Pancreas downstream to the tumor (n = 25)**
CT pattern of tumor attenuation Hyperdense Hypodense Isodense Hyperdense Hypodense Isodense
PPP 9 (23.7) 22 (57.9) 7 (18.4) - 25 (100) -
PVP 5 (13.1) 24 (63.2) 9 (23.7) - 22 (88) 3 (12)
DP 10 (26.3) 7 (18.4) 21 (55.3) 6 (24) 14 (56) 5 (20)
PPP: pancreatic parenchymal phase; PVP = portal venous phase; DP = delayed phase. *CT/histologic assessment in 38/38 patients; **CT/histologic assessment in
25/38 patients. Number in brackets indicates the percentage.
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lease13.0, SPSS Chicago, III).Results
The PDAs ranged in size (maximum diameter on the
axial plane) from 1.2 to 2.0 cm (mean, 1.85 cm). PDA was
located at the head (n = 17), uncinate process (n = 7), neck
(n = 6) and body (n = 8) of the pancreas. Dilatation of main
pancreatic duct (diameter ranged from 4 to 14 mm, mean
6.9 mm) was detected in 23 of 38 patients (60.5%).
The results of tumor appearance (hyper-, iso- and hypo-
dense) at qualitative analysis in each CT phase with respect
to pancreas upstream (n = 38) and downstream (n = 25)
are shown in Table 1.
At qualitative analysis the PDA was isodense to the pan-
creas upstream to the tumor on PPP in 10/38 (26.3%), on
PVP in 12/38 (31.6%) and on DP in 22/38 cases (57.9%).
On qualitative triphasic CT analysis, small PDAs were iso-
dense to the pancreas upstream to the tumor in 8 cases
(8/38; 21%); on DP were detected 2 PDAs isoattenuating
on PPP and PVP. The PDA was hypodense to the pan-
creas downstream to the tumor in 25/25 (100%) cases on
PPP, hypodense and isodense on PVP in 22/25 (88%) and
in 3/25 (12%) respectively and hypodense and hyperdense
on DP in 14/25 (56%) and in 6/25 cases (24%) respectively.
The results of tumor appearance (hyper-, iso- and hypo-
dense) at quantitative analysis in each CT phase with
respect to pancreas upstream (n = 38) and downstream
(n = 25) is shown in Table 2.
On quantitative triphasic CT analysis, small PDAs were
isodense to the pancreas upstream to the tumor, and
therefore unrecognizable, in 4 cases (4/38; 10,5%).Table 3 Attenuation values (HU) related to diagram 1, of
tumor, pancreas upstream and pancreas downstream to
the tumor at triphasic CT
Pre-C PPP PVP DP
Tumor 37 ± 9.7 64 ± 22.6 82 ± 26.1 89.6 ± 23.2
Pancreas upstream 22.2 ± 12.2 83 ± 27 106 ± 23.7 100.8 ± 23.4
Pancreas
downstream
38.8 ± 11.1 121 ± 35.5 110.4 ± 19.7 91.9 ± 16.1
Pre-C. pre-contrast; PPP: pancreatic parenchymal phase; PVP = portal venous phase;
DP = delayed phase.The mean attenuation values (HU ± SD) of PDA, pan-
creatic parenchyma upstream and downstream are shown
in Table 3 and Additional file 1.
Tumor shows progressive enhancement throughout the
three phases with maximum peak in DP; pancreatic paren-
chyma upstream to the tumor shows maximum enhance-
ment in PVP that gradually decreases in DP; pancreatic
parenchyma downstream to the tumor shows maximum
enhancement peak during PPP followed by a rapid decline
on PVP and DP.
The mean attenuation values (HU ± SD) of pancreas up-
stream to the tumor were significantly higher than those
of PDA on PPP, PVP and DP (p < 0.05) whereas the mean
attenuation values of parenchyma downstream to the
tumor were significantly higher than those of tumor in
PPP and PVP (p < 0.05) but not significantly different in
DP (p > 0.05).
The comparisons of the differences of mean attenuation
values between PDA and pancreas upstream and down-
stream to the tumor on PPP, PVP and DP are shown in
Additional file 2.
The difference in attenuation between tumor and par-
enchyma upstream was at least 10 HU on PPP in 31/38
patients (sensitivity = 81.6%), on PVP in 29/38 (sensitiv-
ity = 76.3%) and on DP in 17/38 (sensitivity = 44.7%).
The difference in attenuation between tumor and paren-
chyma downstream was at least 10 HU on PPP in 25/25
patients (sensitivity = 100%), on PVP in 22/25 (sensitivity =
88%) and on DP in 20/25 (sensitivity = 80%).
Diagnostic indices of CT sensitivity in PDA detection on
PPP, PVP and DP are summarized in Table 4. The quantita-
tive analysis by triphasic CT increases the results of qualita-
tive analysis in PDA detection with a sensitivity of 100% in
PDA detection when pancreas downstream is considered.Table 4 Diagnostic indices of triphasic CT sensitivity for
detection of pancreatic ductal adenocarcinoma
PPP PVP DP
Tumor vs upstream (n = 38)* 31/38 (81.6) 29/38 (76.3) 17/38 (44.7)
Tumor vs downstream
(n = 25)**
25/25 (100) 22/25 ( 88) 20/25 (80)
PPP: pancreatic parenchymal phase; PVP = portal venous phase; DP = delayed
phase. *CT/histologic assessment in 38/38 patients; **CT/histologic assessment
in 25/38 patients. Number in the brackets indicates the percentage.
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and pancreatic parenchyma upstream and downstream,
type 1 pattern (enhancement peak during PPP followed by
a rapid decline on PVP and DP) was revealed only in pan-
creas downstream in 19/25 cases (76%), type 2 pattern
(a maximum enhancement in PVP that gradually decreases
in DP) was revealed in PDA in 5/38 cases (13,2%), in pan-
creas upstream in 20/38 cases (52,6%) and in pancreas
downstream in 6/25 cases (24%), while type 3 pattern en-
hancement (a progressive enhancement throughout the
three phases with maximum peak in DP) was revealed inFigure 1 Pancreatic ductal adenocarcinoma of the neck of the pancre
and mild chronic pancreatitis of pancreas upstream and downstream
(HδE 100X) (a), ductal pancreatic adenocarcinoma with intense severe desm
and extensive inflammatory infiltrate with mild fibrosis in downstream pancre
with maximum peak on delayed phase of the upstream pancreatic tissue (arr
maximum enhancement in pancreatic parenchymal phase that gradually dec
dilatation of main pancreatic duct in the pancreas upstream to the tumor.PDA in 33/38 cases (86,8%) and in pancreas upstream in
18/38 cases (47,4%).
The correlation between histopathological characteris-
tics and TDCs for PDA, pancreas upstream and down-
stream shows that type 1 pattern corresponds to normal
pancreas, type 2 pattern corresponds to mild chronic
pancreatitis or PDA with mild fibrous stroma and type 3
pattern corresponds to severe chronic pancreatitis or
PDA with abundant fibrous stroma.
A representative case of severe chronic pancreatitis in
pancreas upstream to PDA and mild chronic pancreatitisas: histology with triple-phase helical CT correlation in severe
respectively. Severe diffuse fibrosis of upstream pancreatic tissue
oplastic stromal reaction consisting of dense collagen (HδE 100X) (b),
as (HδE 100X) (c) and correspective pattern of progressive enhancement
ow in d, e, f), pancreatic ductal carcinoma (arrow in g, h, i) and
reases on portal and delayed phase on CT (arrow in l, m, n). Note
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in pancreas upstream to PDA are reported in Figures 1
and 2 respectively.
Discussion
Despite the recent advances in imaging and treatment,
pancreatic ductal adenocarcinoma (PDA) continues to be
a lethal disease. Recently, some studies reported PDA so
called “isodense” on CT in 5–45% of cases and emphasize
the ancillary sign (eg. main pancreatic duct dilatation or
the interrupted duct sign) in the detection of these tumors
[4,5,7,8].
The misdiagnosis owing to obscurity of a tumor on
CT scan is related to the histopathological characteristics
of the tumor [8,10,11] and surrounding pancreatic par-
enchyma [5].
CT enhancement of the PDA and surrounding pancreatic
parenchyma to the tumor is correlated to the their degree
of fibrosis. PDA with predominant fibrous component,
such as intrahepatic cholangiocarcinoma, shows retention
of contrast material [12-16]. A similar degree of fibrosis inFigure 2 Pancreatic ductal adenocarcinoma of the uncinate process o
in mild chronic pancreatitis of the pancreas upstream. Extensive mild f
ductal adenocarcinoma with severe fibrous stromal reaction (HδE 100×) (b
upstream pancreatic tissue (c-e) and increasing pattern for pancreatic duct
pancreas upstream to the tumor.the tumor and surrounding pancreatic parenchyma may
determine an overlapping enhancement on MDCT that
may preclude the detection of PDA, especially for small
(≤ 2 cm) lesions.
Normal pancreatic parenchyma and mild chronic pan-
creatitis of pancreas downstream to PDA is related to
regular and partial obstruction of drainage of this segment
into the main duct through the accessory one respectively.
Main duct obstruction leads to a framework of obstruct-
ive chronic pancreatitis characterized by ductal dilatation
and fibrous replacement of variable degree (mild or se-
vere) of parenchyma upstream [10,11].
Few studies emphasize the usefulness of triphasic hel-
ical CT to differentiate the enhancement of pancreatic
parenchyma and PDA [17]. Recently, Ishigami et al. [18],
using triphasic MDCT technique, based on the retention
of contrast material due to the fibrotic-stromal component
of PDA, emphasized the usefulness of DP at 5 minutes for
an optimal detection of small PDA visually isoattenuating
on PPP. Moreover, a lot of articles regarding the use of CT
perfusion for detection of PDA are available in recentf the pancreas: histology with triple-phase helical CT correlation
ibrosis in the upstream pancreatic tissue (HδE 100×) (a) and pancreatic
). CT shows maximum enhancement on portal venous phase for
al adenocarcinoma (f-h). Note dilatation of main pancreatic duct in the
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perfusion (CTp) imaging is a promising technique that al-
lows functional imaging, as an adjunct to a morphologic
CT examination, the measurements obtained with the CT
perfusion software and their upgrades are not currently
consistent and reproducible.
Our data show that type 1 pattern (normal pancreas) was
observed only in downstream pancreas: this means that
when pancreatic parenchyma downstream to the tumor is
evaluable, the difference in attenuation between this one
and the tumor allows the detection of PDA in all cases
(38/38 patients; sensitivity of 100%). Otherwise, a coexisting
pancreatitis in the pancreatic parenchyma upstream to the
tumor, a very frequent condition, makes diagnosis difficult
because of the overlapping of the attenuation values be-
tween the tumor and pancreas upstream.
According to our experience, small PDAs were iso-
dense to the pancreas upstream to the tumor, and there-
fore unrecognizable, in 8 cases (8/38; 21%) at qualitative
analysis and in 4 cases (4/38; 10,5%) at quantitative ana-
lysis; on DP two PDAs not detected on PPP and PVP
were revealed.
The quantitative analysis at triphasic MDCT increases
tumor detection with respect to visual analysis, showing
a higher sensitivity in all phases, even for small PDAs
isodense to the pancreatic parenchyma upstream to the
tumor.
Our study has some limitations:
1) the retrospective nature of the study including a
limited (38/127) selected patients with histologically
proved PDA in which the relationship between
enhancement and histopathology was obtained;
2) the characteristics of patients enrolled in the study,
which were all surgically treated patients for a small
PDA detected at MDCT, not including patients with
an hypothetical misdiagnosis;
3) the DP at 5 minutes increases the radiation dose to
the patient. Although recently has been proposed
split-bolus CT protocol of the pancreas to reduce
dose radiation, the DP is useful in the detection of
visually isoattenuating lesions on PPP or on PVP
[17,20-22] establishing the presence of obstructive
chronic pancreatitis in the surrounding pancreas to
the tumor.Conclusions
In conclusion the knowledge of the histologic features and
enhancement patterns of PDA and surrounding pancreas
at CT could be essential for improve research on methods
to detect isoattenuating tumor. Our preliminary study
shows that the quantitative analysis of the enhancement
for PDA and surrounding parenchyma may be consideredin order to increase the sensitivity of CT in the detection
of small PDA.Additional files
Additional file 1: Time-density-curves of tumor, pancreas upstream
and pancreas downstream to the tumor at triphasic CT. Time-
density-curves show the tumor with a progressive enhancement
throughout the three phases with maximum peak in DP; pancreatic
parenchyma upstream to the tumor shows maximum enhancement in
PVP that gradually decreases in DP; pancreatic parenchyma downstream
to the tumor shows maximum enhancement peak during PPP followed
by a rapid decline on PVP and DP. The mean attenuation values (HU ± SD)
of pancreas upstream to the tumor were significantly higher than those of
PDA on PPP, PVP and DP (p < 0.05) whereas the mean attenuation values of
parenchyma downstream to the tumor were significantly higher than those
of tumor in PPP and PVP (p < 0.05) but not significantly different in DP
(p > 0.05). Pre-C: pre-contrast; PPP: pancreatic parenchymal phase; PVP = portal
venous phase; DP = delayed phase.
Additional file 2: Comparison of difference in mean attenuation
(HU) between tumor and pancreas upstream and downstream to
the tumor at triphasic CT. The dashed lines indicate the minimum
difference of enhancement (10 HU) to detect the tumor respect to the
surrounding pancreatic parenchyma. Pre-C: pre-contrast; PPP: pancreatic
parenchymal phase; PVP = portal venous phase; DP = delayed phase.
p-Up: pancreas upstream to the tumor; p-Down: pancreas downstream
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